Eating disorders are on the rise. GLP-1s could make things worse.

Global incidence of anorexia nervosa and bulimia nervosa rose 71% between 1990 and 2023, according to a new report. Clinical psychologists warn that GLP-1 weight-loss drugs, a major biotech breakthrough, may trigger eating disorders in some patients. The report highlights a potential dark side to the popular medications as their use expands.